R-Biopharm AG and Gold Standard Diagnostics, Corp. Announce Strategic Alliance:
Companies will co-develop new diagnostic products and will establish global marketing collaboration.
Newswise — DAVIS, California, (June 23, 2016) — Gold Standard Diagnostics, Corp. (GSD) announced today a strategic alliance with R-Biopharm AG (Darmstadt, Germany) to collaborate on multiple technology and marketing initiatives that will leverage the companies’ respective strengths in expanding product offerings and geographic sales coverage.
Under this arrangement, GSD will be the exclusive distributor for R-Biopharm’s Clinical diagnostics products in the U.S. GSD has broad U.S. market coverage, through its national channel partners, in key clinical segments that include hospitals, POL’s and reference laboratories. This initiative expands GSD’s strategic vision of collaborating with technology leaders in bringing differentiated solutions to the market by adding content to GSD’s automated instrument platforms.
R-Biopharm has a broad portfolio of products, in multiple technology formats, which are complementary to GSD’s expertise in instrument development. This partnership will give R-Biopharm access to GSD products, including its instrumentation platforms and diagnostic test kits, to enhance their offering to their worldwide distribution network spread over 130 countries.
The two companies will also collaborate on several strategic projects for the U.S. and International markets that will leverage their respective strengths in developing transformative technologies that establish strong market niches. R-Biopharm’s network of subsidiaries and GSD’s select supplier base will present opportunities that will drive innovative concepts in delivering diagnostic solutions. GSD will also add to this partnership with its expertise in clearing products through the FDA.
John Griffiths, CEO of GSD, comments “We look forward to partnering with R-Biopharm, who has a strong track record of growing their business organically and through strategic acquisitions. RBIO is a globally-recognized leader in developing assays for the Clinical Diagnostics and Food & Feed testing markets. This alliance will also fast track innovation and investment in new technologies.”
Ralf Dreher, CEO of R-Biopharm, said “The partnership between R-Biopharm and Gold Standard Diagnostics will enable both companies to strengthen their position as solution providers in North America and the Global Market. GSD has an outstanding reputation in clinical business in the USA and can look back on many years of experience in laboratory equipment and automation. The synergy born out of this cooperation will set new standards in clinical diagnostics, which will also be highly beneficial for the customer. “
About Gold Standard Diagnostics, Corp..
Gold Standard Diagnostics, Corp., is a privately held clinical diagnostics company based in Davis, California. The company develops, manufactures and distributes an innovative portfolio of instrumentation and diagnostic products to clinical laboratories Worldwide. Since launching the ThunderBolt in 2012, GSD has released 4 new instrumentation platforms, with over 600 installations, including an open EIA+CLIA combination instrument, and the AIX1000, the first fully automated system for performing RPR (Rapid Plasma Reagin) syphilis tests. With many projects in the pipeline, the next expected launch is of the Bolt, a one plate open system to meet the needs of low volume customers. GSD also develops and offers an extensive menu of serology tests used in the areas of autoimmune disease, infectious disease and endocrinology, and is continuously building its pipeline of innovative products.
About R-Biopharm AG
R-Biopharm possesses many years of sound experience in the Clinical diagnostics market, particularly in the field of infectious stool diagnostics as well as in the field of serological infection diagnostics and allergy diagnostics. In 2006 the clinical product portfolio was extended by innovative test systems in the tumor diagnostics and gastroenterology product lines. R-Biopharm is a successful global player and is constantly developing new and groundbreaking test systems in different areas, Process automation being a main focus from the beginning. All distributed tests are validated and CE-marked.
R-Biopharm’s distinctive policy of partnership and teamwork is an approach valued by its customers and research partners alike. The company’s key objective is to be a dependable point of contact for customers, providing competent advice on every sector it serves.
At R-Biopharm the future is set to offer further exciting prospects in the fields of clinical diagnostics and food and feed analysis. The foremost challenge is to advance the development of new and versatile fast tests. These will shorten the time it takes to obtain results from a wide range of analytical procedures.
Contact:Gold Standard Diagnostics, Corp.. Jim Thompson530-759-8000[email protected]
RSS